All In Biotech

Drug Trial Radar · NCT07288034

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Immunotherapy Biomarker Collection for Metastatic NSCLC to Inform Adaptive Personalized Models Targeting Resistance (IMMUNO-BIOMAP)

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 535 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

535

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Oct 8, 2028

Study completion Oct 8, 2028

Sponsor

Lead sponsor
City of Hope Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests the impact of biomarkers in predicting initial treatment (first-line) PD1 or PD-L1 (PD\[L\]-1)-based immunotherapy response and in selecting second-line treatment in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Response and survival rates in advanced stage NSCLC, unlike other cancers, rely on response to first-line therapy. Immunotherapy with PD(L)1-based therapy, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. While immunotherapy has improved survival rate, the prognosis remains poor with most patients receiving chemotherapy after immunotherapy. Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid (DNA) which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. The first part of this trial, studying samples of blood and tissue in the laboratory from patients receiving immunotherapy may help doctors learn more about the effects PD(L)1-based therapy on cells. It may also help doctors understand how well patients respond to treatment and may help develop new individualized treatment strategies. The second part of this trial also tests the effect of second-line immunotherapy, such as tremelimumab and durvalumab or adagrasib and bevacizumab, in treating patients with NSCLC with specific genetic mutations that is growing, spreading or getting worse (progressive). Tremelimumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adagrasib, a type of targeted therapy, may stop the growth of tumor cells by blocking a protein needed for tumor cell growth and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving second-line immunotherapy, tremelimumab and durvalumab or adagrasib with bevacizumab, may be safe, tolerable, and/or effective in treating patients with stage IIIB/IV NSCLC with specific genetic mutations.

Conditions

  • Lung Non-Small Cell Carcinoma
  • Stage IIIB Lung Cancer AJCC v8
  • Stage IV Lung Cancer AJCC v8

Interventions

  • AdagrasibDrug

    Given PO

  • Anti-PD-L1 Monoclonal AntibodyBiological

    Given PD-L1-based immunotherapy

  • Anti-PD1 Monoclonal AntibodyBiological

    Given PD1-based immunotherapy

  • BevacizumabBiological

    Given IV

  • Biopsy ProcedureProcedure

    Undergo tumor biopsy

  • Biospecimen CollectionProcedure

    Undergo blood, CSF, ascites and pleural fluid sample collection

  • ChemotherapyDrug

    Given chemotherapy

  • Computed TomographyProcedure

    Undergo CT

  • DurvalumabBiological

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo PET

  • MonitoringOther

    Undergo monitoring

  • Positron Emission TomographyProcedure

    Undergo PET

  • SurveillanceBehavioral

    Undergo close surveillance

  • TremelimumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) during first-line treatment (Part I)Time frame: From the start of randomization to disease progression or death from any cause, whichever occurs first, assessed up to 3 years
  2. PFS by arm for second-line treatment (Part II)Time frame: From the start of treatment to disease progression or death from any cause, whichever occurs first, assessed up to 3 years

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • CTCA at Western Regional Medical Center

    Goodyear, Arizona · Recruiting

  • City of Hope Corona

    Corona, California · Recruiting

  • City of Hope Medical Center

    Duarte, California · Recruiting

  • City of Hope Seacliff

    Huntington Beach, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • City of Hope Antelope Valley

    Lancaster, California · Recruiting

  • City of Hope at Long Beach Elm

    Long Beach, California · Recruiting

  • City of Hope at Newport Beach Fashion Island

    Newport Beach, California · Recruiting

  • City of Hope South Pasadena

    South Pasadena, California · Recruiting

  • City of Hope South Bay

    Torrance, California · Recruiting

  • City of Hope Upland

    Upland, California · Recruiting

  • City of Hope Atlanta Cancer Center

    Newnan, Georgia · Recruiting

  • City of Hope at Chicago

    Zion, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.